[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE03122B1 - Nikotiinhappe estrid, nende valmistamismeetod ja farmatseutiline kompositsioon - Google Patents

Nikotiinhappe estrid, nende valmistamismeetod ja farmatseutiline kompositsioon

Info

Publication number
EE03122B1
EE03122B1 EE9400400A EE9400400A EE03122B1 EE 03122 B1 EE03122 B1 EE 03122B1 EE 9400400 A EE9400400 A EE 9400400A EE 9400400 A EE9400400 A EE 9400400A EE 03122 B1 EE03122 B1 EE 03122B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
acid esters
nicotinic acid
saturated
Prior art date
Application number
EE9400400A
Other languages
English (en)
Estonian (et)
Inventor
Chang Wu Jin
Lundstedt Torbj�rn
Abramo Lisbeth
Bj�rk Anders
Pettersson G�ran
Andersson Gunnar
Nordvi Curt
Ludwig Catarina
Seifert Elisabeth
Nilsson Arne
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of EE03122B1 publication Critical patent/EE03122B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EE9400400A 1992-06-25 1994-11-17 Nikotiinhappe estrid, nende valmistamismeetod ja farmatseutiline kompositsioon EE03122B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201956A SE9201956D0 (sv) 1992-06-25 1992-06-25 Novel nicotinicacid esters

Publications (1)

Publication Number Publication Date
EE03122B1 true EE03122B1 (et) 1998-10-15

Family

ID=20386602

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400400A EE03122B1 (et) 1992-06-25 1994-11-17 Nikotiinhappe estrid, nende valmistamismeetod ja farmatseutiline kompositsioon

Country Status (27)

Country Link
US (1) US5658910A (de)
EP (2) EP1120410B1 (de)
JP (1) JP3306827B2 (de)
KR (1) KR100302216B1 (de)
CN (1) CN1085981C (de)
AT (2) ATE278671T1 (de)
AU (1) AU681346B2 (de)
BG (1) BG62000B1 (de)
CA (1) CA2139112C (de)
CZ (1) CZ281975B6 (de)
DE (2) DE69331234T2 (de)
DK (1) DK0673368T3 (de)
EE (1) EE03122B1 (de)
ES (1) ES2169044T3 (de)
FI (1) FI107151B (de)
HU (2) HU220613B1 (de)
IL (1) IL106135A (de)
NO (1) NO302945B1 (de)
NZ (1) NZ253823A (de)
PH (1) PH31417A (de)
PT (1) PT673368E (de)
RO (1) RO115725B1 (de)
RU (1) RU2127732C1 (de)
SE (1) SE9201956D0 (de)
SK (1) SK279393B6 (de)
WO (1) WO1994000434A1 (de)
ZA (1) ZA934596B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
MX2020011960A (es) * 2018-05-09 2021-01-15 Lg Chemical Ltd Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives

Also Published As

Publication number Publication date
NZ253823A (en) 1996-01-26
AU681346B2 (en) 1997-08-28
PH31417A (en) 1998-10-29
ZA934596B (en) 1994-02-14
SK158594A3 (en) 1995-07-11
JP3306827B2 (ja) 2002-07-24
WO1994000434A1 (en) 1994-01-06
DE69331234D1 (de) 2002-01-10
SK279393B6 (sk) 1998-11-04
DE69333655D1 (de) 2004-11-11
ATE278671T1 (de) 2004-10-15
IL106135A0 (en) 1993-10-20
SE9201956D0 (sv) 1992-06-25
JPH07508517A (ja) 1995-09-21
NO945022L (no) 1995-02-13
IL106135A (en) 1999-01-26
CN1085981C (zh) 2002-06-05
EP1120410A1 (de) 2001-08-01
CZ327494A3 (en) 1995-09-13
ES2169044T3 (es) 2002-07-01
DE69331234T2 (de) 2002-08-08
EP1120410B1 (de) 2004-10-06
EP0673368B1 (de) 2001-11-28
EP0673368A1 (de) 1995-09-27
HU220613B1 (hu) 2002-03-28
BG62000B1 (bg) 1998-12-30
FI946085A0 (fi) 1994-12-23
RU94046310A (ru) 1996-10-27
CN1086811A (zh) 1994-05-18
RO115725B1 (ro) 2000-05-30
ATE209634T1 (de) 2001-12-15
CA2139112A1 (en) 1994-01-06
CZ281975B6 (cs) 1997-04-16
HU210875A9 (en) 1995-08-28
HU9403786D0 (en) 1995-02-28
PT673368E (pt) 2002-05-31
FI107151B (fi) 2001-06-15
DK0673368T3 (da) 2002-03-18
FI946085A (fi) 1994-12-23
KR100302216B1 (ko) 2001-11-22
NO302945B1 (no) 1998-05-11
US5658910A (en) 1997-08-19
CA2139112C (en) 2006-03-21
BG99289A (bg) 1995-09-29
RU2127732C1 (ru) 1999-03-20
AU4519393A (en) 1994-01-24
KR950702186A (ko) 1995-06-19
HUT71406A (en) 1995-11-28
NO945022D0 (no) 1994-12-23

Similar Documents

Publication Publication Date Title
ATE136882T1 (de) Carbamidsäureester-derivate, mittel und herstellungsverfahren
NZ336202A (en) Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
EE03122B1 (et) Nikotiinhappe estrid, nende valmistamismeetod ja farmatseutiline kompositsioon
DE3368050D1 (en) Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
IE893211L (en) Benzoxazepinone Process
BR8502885A (pt) Processo para preparar acido azetidino-3-carboxilico,seus derivados e usos
DE3569926D1 (de) Derivatives of n-û2-(tetrahydro-3,5-dioxo-1h-pyrrolizin-7a(5h)-yl)ethyl¨amine
ATE130838T1 (de) Derivate der 4-(2,4-difluorbiphenyl)-2-methyl-4- oxobutansäure.
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.
GEP19971013B (en) Novel pyridyl and pyrimidyl derivatives process for preparing thereof, and treatment method for mental disorder
DK0627419T3 (da) Optisk aktive derivater af 1-phenylpyrrolidon og fremgangsmåde til fremstilling deraf
GEP19981536B (en) Process for the Preparation of 1-Ethyl-1(Hydroxymethyl)-1,2,3,4,6,7,12,12-Octahydro-Indolo [2,3-) Quinolizine and Novel Intermediates ^

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20091117